stoxline Quote Chart Rank Option Currency Glossary
  
Azitra, Inc. (AZTR)
0.1699  -0.064 (-27.87%)    06-18 10:40
Open: 0.1905
High: 0.1998
Volume: 8,493,810
  
Pre. Close: 0.2337
Low: 0.1521
Market Cap: 5(M)
Technical analysis
2024-06-18 10:17:38 AM
Short term     
Mid term     
Targets 6-month :  0.26 1-year :  0.32
Resists First :  0.22 Second :  0.27
Pivot price 0.17
Supports First :  0.14 Second :  0.11
MAs MA(5) :  0.16 MA(20) :  0.17
MA(100) :  0.32 MA(250) :  1.38
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  30.8 D(3) :  22.6
RSI RSI(14): 45
52-week High :  4.94 Low :  0.14
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AZTR ] has closed above bottom band by 39.7%. Bollinger Bands are 74% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 72 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.28 - 0.28 0.28 - 0.28
Low: 0.14 - 0.14 0.14 - 0.14
Close: 0.23 - 0.23 0.23 - 0.24
Company Description

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

Headline News

Mon, 17 Jun 2024
Is Azitra Inc (AZTR) a good investment opportunity? – US Post News - US Post News

Mon, 10 Jun 2024
Azitra Inc (AZTR) Stock: A Year of Highs and Lows - The InvestChronicle

Wed, 05 Jun 2024
Azitra (NYSEAMERICAN:AZTR) Stock Price Down 6.3% - Defense World

Mon, 03 Jun 2024
Balance Sheet Insights: Azitra Inc (AZTR)'s Debt-to-Equity and Long-Term Debt/Eq Ratios – DWinneX - The Dwinnex

Sun, 19 May 2024
AZTR Stock Price and Chart — AMEX:AZTR - Azitra Inc - TradingView

Fri, 16 Feb 2024
Azitra Inc Announces Public Offering and Share Lock-Up Period - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 12 (M)
Shares Float 3 (M)
Held by Insiders 7 (%)
Held by Institutions 56.5 (%)
Shares Short 4 (K)
Shares Short P.Month 3 (K)
Stock Financials
EPS -1.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.43
Profit Margin 0 %
Operating Margin -641.7 %
Return on Assets (ttm) -57.5 %
Return on Equity (ttm) -379.7 %
Qtrly Rev. Growth 540.5 %
Gross Profit (p.s.) 0.02
Sales Per Share 0.05
EBITDA (p.s.) -0.63
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -0.14
PEG Ratio 0
Price to Book value 0.36
Price to Sales 3.1
Price to Cash Flow -0.29
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android